Skip to main content
. 2022 Apr 5;15(4):450. doi: 10.3390/ph15040450

Table 4.

Cell lines used and maximum tracer uptake for EGFR TKI PET tracers not based on clinically approved EGFR TKIs.

Cell Line Tissue Disease EGFR Status Other
Mutations [41]		 Tracer Maximum Tracer Uptake
U87 (U87MG) Brain Likely glioblastoma Low amount of wild-type EGFR IDH1, NF1, PTEN, TERT, TP53 [18F]ML04 Transfected with EGFR: 0.92 ± 0.03%ID/g, T/B 6.97 ± 0.52, T/M 5.11 ± 0.29 at 3h [52]
ML04-PEG4-[18F]F Transfected with EGFR: Not specified [53]
[11C]ML04-PEG4-OH Transfected with EGFR: Not specified [53]
[124I]IPQA-PEG4-OH Transfected with EGFR: Not specified [53]
U138MG Brain Glioblastoma EGFR-negative CDKN2A, IDH1, PTEN, TP53 [18F]ML04 0.68%ID/g at 3h [52]
ML04-PEG4-[18F]F Not specified [53]
[11C]ML04-PEG4-OH Not specified [53]
[124I]IPQA-PEG4-OH Not specified [53]
H441 Lung Papillary adenocarcinoma Wild-type EGFR KRAS, TP53 IPQA-PEG6-[18F]F 1.59 ± 0.06 %ID/g, T/M 1.47 ± 0.09 at 120 min [54]
[77Br]Br-CO1686 3.71 ± 0.13 %ID/g at 60 min [55]
[125I]I-CO1686 0.44 ± 0.06 %ID/g at 60 min [55]
H1975 Lung Adenocarcinoma; NSCLC L858R/T790M PIK3CA, TP53 IPQA-PEG6-[18F]F 1.17 ± 0.18%ID/g, T/M 1.05 ± 0.10 at 120 min [54]
[18F]MPG 3.93 ± 0.44%ID/g at 60 min, T/M ratio not specified [56]
[18F]APP-1 T/M 2.95 at 180 min [57]
[18F]F-IRS 1.71 ± 0.18%ID/g at 120 min [58]
6-O-[18F]FEE SUV of 0.5 at 60 min [59]
[125I]I-CO1686 1.77 ± 0.43%ID/g[60], 0.68 ± 0.11%ID/g at 60 min [55]
[77Br]Br-CO1686 4.51 ± 0.17%ID/g at 60 min [55]
[125I]I-osimertinib 1.97 ± 0.30%ID/g at 4h [61]
[77Br]Br-osimertinib 1.96 ± 0.33%ID/g at 4h [61]
H3255 Lung Adenocarcinoma L858R TP53 IPQA-PEG6-[18F]F 2.34 ± 0.13%ID/g, T/M 2.08 ± 0.19 at 120 min [54]
[18F]APP-1 3.80 ± 0.88%ID/g, T/M 13.37± 4.02 at 180 min [57]
[125I]I-CO1686 1.63 ± 0.23%ID/g at 60 min [60]
[125I]I- osimertinib 2.93 ± 0.11%ID/g at 4h [61]
[77Br]Br-osimertinib 3.42 ± 0.05%ID/g at 4h [61]
PC14 * Lung; Lymph node Adenocarcinoma Del19 TP53 IPQA-PEG6-[18F]F 0.99 ± 0.18%ID/g, T/M 0.9 ± 0.11 at 120 min [54]
K562 Bone marrow Chronic myelogenous leukemia Low amount of wild-type EGFR BCR-ABL1, TP53 Morpholino-[124I]IPQA rats: 0.20 ± 0.03%ID/g, T/M 1.25 at 60 min [62]
mice: 0.43 ± 0.02%ID/g, T/M 1.79 at 69 min [62]
A431 Skin/
epidermis		 Epidermoid carcinoma EGFR-PPARGC1A fusion TP53 Morpholino-[124I]IPQA rats: 0.72 ± 0.12%ID/g, T/M 4.52 at 60 min [62]
mice: 1.32 ± 0.26%ID/g, T/M 5.8 at 69 min [62]
H1299 Lung; lymph node Carcinoma; NSCLC Wild-type EGFR TP53, NRAS Morpholino-[131I]IPQA Transfected with L858R: 0.28 ± 0.00%ID/g, Del19: 0.30 ± 0.00%ID/g, EGFR: 0.35 ± 0.00%ID/g, Vector: 0.22 ± 0.00%ID/g at 60 min [63]
HCC827 Lung Adenocarcinoma Del19 TP53 [18F]MPG 7.22 ± 0.28%ID/g, T/M 5.56 at 60 min [56]
[18F]F-FEA-erlotinib 0.70 ± 0.37%ID/g at 15 min, T/M 3.19 ± 0.5 at 60 min [64]
6-O-[18F]FEE SUV of 1.0 at 60 min [59]
[18F]F-IRS 4.27 ± 0.15 %ID/g at 120 min [58]
H520 Lung Squamous cell carcinoma EGFR-negative ATM, CDKN2A, TP53 [18F]MPG
[18F]F-IRS		 3.59 ± 0.93%ID/g at 60 min, T/M ratio not specified [56]
1.62 ± 0.08%ID/g at 120 min [58]
H358 Lung /bronchiole bronchioalveolar carcinoma: NSCLC Wild-type EGFR TP53, KRAS [18F]MPG
[18F]F-IRS		 4.11 ± 0.46%ID/g at 60 min, T/M ratio not specified [56]
1.68 ± 0.29%ID/g at 120 min [58]
QG56 Lung Squamous cell carcinoma Wild-type EGFR TP53 6-O-[18F]FEE SUV of 0.3 at 60 min [59]
S180 Murine Sarcoma [18F]icotinib derivative 1a 1.61 ± 0.33%ID/g, T/M 1.45 at 30 min [65]
[18F]icotinib derivative 1b 4.70 ± 0.23%ID/g, T/M 2.3 at 30 min [65]
[18F]icotinib derivative 1c 3.06 ± 0.22%ID/g, T/M 1.11 at 30 min [65]
A549 Lung Carcinoma Wild-type EGFR KRAS, STK11, TP53 [18F]icotinib derivative 1d 0.90 ± 0.24%ID/g at 90 min [66]

* PC14 short tandem repeat DNA profile analysis showeed this cell line to be identical to PC-9.